All In Biotech

Drug Trial Radar · NCT05946642

Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso

Clinical Trial to Evaluate Efficacy and Safety of Sulfadoxine/Pyrimethamine-Amodiaquine and Dihydroartemsinin-Piperaquine Plus Ivermectin Administered Monthly as Intermittent Preventive Treatment in School-aged Children in Burkina Faso

Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 13,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

13,000

Planned (sponsor's estimate)

Start

Jul 15, 2023

Primary completion

May 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Malaria ConsortiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be an open label cluster randomized study with two active intervention and one control arm. A cluster will be defined as a selected village. One district implementing seasonal malaria chemoprevention (SMC) will be selected, and six villages will be randomly selected in this district. These six villages will be randomly allocated to each of the three study arms; 1) Arm 1 will receive IPTsc with sulphadoxine-pyrimethamine plus amodiaquine (SPAQ); and 2) Arm 2 will receive dihydroartemisinin-piperaquine (DP) plus Ivermectin (IVM), all given monthly during the transmission season and 3) Control Arm which will have standard malaria control measures including case management and vector control measures as applicable.

Conditions

  • Malaria

Interventions

  • Sulphadoxine-Pyrimethamine/AmodiaquineDrug

    Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.

  • Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)Drug

    DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin. Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of symptomatic malaria in children of the target age group by microscopy and molecular methods.Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Malaria Consortium

    Ouagadougou, Burkina Faso · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.